# The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics

> **NCT06059287** · NA · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 64 (estimated)

## Conditions studied

- Obesity
- Type 2 Diabetes
- Sodium-glucose Co-transporter-2 Inhibitor
- Myocardial Fibrosis
- Magnetic Resonance Imaging

## Interventions

- **DRUG:** Henagliflozin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT06059287
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06059287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06059287, "The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06059287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*